HOME >> BIOLOGY >> NEWS
Introgen publishes preclinical findings demonstrating the potent anti-tumor properties of INGN 241 study featured on the cover of Molecular Medicine

Austin, TX, May 10, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today the publication of its preclinical studies in the current issue of Molecular Medicine demonstrating the potent anti-tumor effects of INGN 241 (an adenoviral vector encoding the mda-7 gene) in three of the most prevalent human cancers, breast, lung and colorectal.

The study also demonstrates, for the first time, that MDA-7 protein is released from cancer cells treated with Adenoviral-mda7. The lead author of the publication is Abner Mhashilkar, Ph.D., project leader of Introgens mda-7 program. The cover of Molecular Medicine featured a photomicrograph which demonstrates secretion of MDA-7 protein from INGN 241 treated cells, a result which may enhance the potency of INGN 241 therapy.

The research and paper are the result of the efforts of an international team of collaborators, including scientists from The University of Texas M. D. Anderson Cancer Center, the Imperial Cancer Research Technology in the United Kingdom, Corixa Corporation and Columbia University College of Physicians and Surgeons. The study was funded in part by grant R43 CA86587 from the National Cancer Institute.

We have previously shown that INGN 241 will selectively kill lung tumor cells by inducing the cells to commit suicide, a process known as apoptosis, said Sunil Chada, Ph.D., Introgens director of research and development and senior author of the manuscript. These new functional studies indicate that the mda-7 gene has tumor suppressor activity in some of the most prevalent human cancers. Introgens research also demonstrates that the MDA-7 protein is secreted. These unique properties of INGN 241 suggest that it may be a potent anti-tumor agent for local-regional applications, and potentially for the systemic treatment of cancer.

The studies involved functional biological assays coupled with genomic analytic tools. These studies indicated that INGN 241 suppressed growth in 19 out of
'"/>

Contact: Andi Wakayama
a.wakayama@noonanrusso.com
415-677-4455 ext 252
Noonan/Russo Communications
9-Apr-2001


Page: 1 2 3 4

Related biology news :

1. Introgens gene drug demonstrates tumor growth control
2. New family of 10 cancer related genes discovered by NCI, University of Texas and M.D. Anderson researchers; licensed by Introgen
3. Introgen Therapeutics reports advances in RPR/INGN 201 clinical program for treatment of advanced cancers
4. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting
5. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
6. Warren Pharmaceuticals publishes results of preclinical evaluation
7. Professor publishes book on historic mosquito wars
8. AGI publishes 42nd edition of Directory of Geoscience Departments
9. International HapMap Consortium publishes scientific strategy
10. Ingenium publishes biological characterization of first mouse model for kidney stones
11. OHSU researcher publishes first measurements of free-base nicotine in cigarette smoke

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/27/2018)... (PRWEB) , ... December 27, 2018 , ... ... 60 cervical discs for implantation at its new Boston facility, and is now ... have additional inventory to immediately expand market share against inferior ball and socket ...
(Date:12/20/2018)... PARK, N.C. (PRWEB) , ... December 20, 2018 ... ... been enhanced through upgraded processes and the completion of a new usability/observation room. ... with the goal of ensuring medical devices and drug delivery devices/combination products are ...
(Date:12/18/2018)... PHOENIX (PRWEB) , ... December 18, 2018 , ... ... Cell, has effectively incorporated artificial intelligence into client marketing. The technology has been ... six years, R3 Stem Cell has been working with clients nationwide on patient ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... ... January 07, 2019 , ... Today ... Noninvasix. This represents the second investment AngelMD has made into Noninvasix in the ... is developing a patient monitor to directly, accurately, and noninvasively measure brain oxygenation ...
(Date:1/4/2019)... ... January 02, 2019 , ... ... and cancer cells in blood, has been named as a partner in Medigen ... company developing cell therapies for cancer treatment, will use CellMax Life’s circulating tumor ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
(Date:12/13/2018)... , ... December 12, 2018 , ... ... life science software solutions, announces the Limfinity® ML (Machine Learning) addition for its ... machine learning models within Limfinity® solutions. In the module, trained models make predictions ...
Breaking Biology Technology:
Cached News: